Alligator Bioscience has signed an agreement to sell all rights and assets related to the CD40 agonist antibody mitazalimab to Biossil.   Alligator will receive $750,000 upfront and is eligible for up to $108 million in milestone payments, as well as royalties on future sales, capped at $250 million in total.  Under the agreement, Biossil acquires worldwide […]